Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary objective is to determine if LY2382770, administered monthly for 1 year is more effective than placebo at slowing the progression of diabetic kidney disease in patients treated with angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) administered monthly by subcutaneous injection for 1 year is more effective than placebo at slowing the progressive loss of kidney function, as measured by Serum Creatinine (SCr) change from baseline.
Critère d'inclusion
- Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes